Progress in study of microRNA in inflammatory bowel disease

doi:10.3877/cma.j.issn.2095-3224.2017.03.012

Abstract

Abstract:

Inflammatory bowel disease (IBD) is a chronic non-specific intestinal inflammatory disease, mainly including ulcerative colitis (UC) and crohn′s disease (CD). The etiology of IBD has not yet been clarified, and it may be relevant to many factors. Recent studies have shown that expressions of microRNA (miRNA) were frequently altered in patients with IBD, and were involved in the development of IBD. This article reviewed the aberrant miRNA expressions in patients with IBD in order to discuss the value of miRNA in the pathogenesis, diagnosis and prognosis of IBD, and to further provide the evidence for its clinical application.

Key words: Digestive system, Colitis, ulcerative, Crohn disease, microRNA

Litian Wang, Lisheng Yang, Gang Liu. Progress in study of microRNA in inflammatory bowel disease[J]. Chinese Journal of Colorectal Diseases(Electronic Edition), 2017, 06(03): 230-233.

/ / Recommend

Add to citation manager EndNote|Ris|BibTeX

URL: https://zhjzcjbdzzz.cma-cmc.com.cn/EN/10.3877/cma.j.issn.2095-3224.2017.03.012

https://zhjzcjbdzzz.cma-cmc.com.cn/EN/Y2017/V06/I03/230

References 33

[1]	Abraham C, Medzhitov R. Interactions between the host innate immune system and microbes in inflammatory bowel disease [J]. Gastroenterology, 2011, 140(6):1729-1737.
[2]	Kaser A, Zeissig S, Blumberg R. Inflammatory bowel disease [J]. Annu Rev Immunol, 2010, 28(1):573-621.
[3]	Guarnieri DJ, Dileone RJ.MicmRNAs：a new class of gene regulators [J]. Ann Med, 2008, 40(3):197-208.
[4]	Pekow JR, Kwon JH. MicroRNAs in inflammatory bowel disease [J]. Inflamm Bowel Dis, 2012, 18(1):187-193.
[5]	Polytarchou C, Oikonomopoulos A, Mahurkar S, et al. Assessment of Circulating MicroRNAs for the Diagnosis and Disease Activity Evaluation in Patients with Ulcerative Colitis by Using the Nanostring Technology [J]. Inflamm Bowel Dis, 2015, 21(11):2533-2539.
[6]	Felwick R., Dingley G., Sanchez-Elsner T., et al. MicroRNA23a is overexpressed in the colonic epithelium in Crohn′s disease [J]. Journal of Crohn′s and Colitis , 2016, 150(4):S375-S375.
[7]	Yu Q, Zhang S, Chao K, et al. E3 Ubiquitin ligase RNF183 Is a Novel Regulator in Inflammatory Bowel Disease [J]. J Crohns Colitis, 2016, 10(6):713-725.
[8]	Wu W, He C, Liu C, et al. miR-10a inhibits dendritic cell activation and Th1/Th17 cell immune responses in IBD [J]. Gut, 2015, 64(11):1755-1764.
[9]	Takagi T, Naito Y, Mizushima K, et al. Increased expression of microRNA in the inflamed colonic mucosa of patients with active ulcerative colitis [J]. J Gastroenterol Hepatol, 2010, 25(1):S129-S133.
[10]	Heinsbroek SE, Squadrito ML, Schilderink R, et al. miR-511-3p, embedded in the macrophage mannose receptor gene, contributes to intestinal inflammation [J]. Mucosal Immunol, 2016, 9(4):960-973.
[11]	Zhang L, Shen J, Cheng J, et al. MicroRNA-21 regulates intestinal epithelial tight junction permeability [J]. Cell Biochem Funct, 2015, 33(4):235-240.
[12]	Yang Y, Ma Y, Shi C, et al. Overexpression of miR-21 in patients with ulcerative colitis impairs intestinal epithelial barrier function through targeting the Rho GTPase RhoB [J]. Biochem Biophys Res Commun, 2013, 434(4):746-752.
[13]	Ye D, Guo S, Al-Sadi R, et al. MicroRNA regulation of intestinal epithelial tight junction permeability [J]. Gastroenterology, 2011, 141(4):1323-1333.
[14]	Chen Y, Wang C, Liu Y, et al. miR-122 targets NOD2 to decrease intestinal epithelial cell injury in Crohn′s disease [J]. Biochem Biophys Res Commun, 2013, 438(1):133-139.
[15]	Schaefer JS, Attumi T, Opekun AR, et al. MicroRNA signatures differentiate Crohn′s disease from ulcerative colitis [J]. BMC Immunol, 2015, 16(1):5.
[16]	Krissansen GW, Yang Y, Mcqueen FM, et al. Overexpression of miR-595 and miR-1246 in the sera of patients with active forms of inflammatory bowel disease [J]. Inflamm Bowel Dis, 2015, 21(3):520-530.
[17]	Yu N, Zhang YP, Wang FY. Differential expression of miR-155 as a novel fecal-based diagnostic marker for inflammatory bowel disease [J]. J Dig Dis, 2014, 15, SUPPL. (1):156.
[18]	Yi F, Zhou R, Xun J, et al. The utility of fecal microRNAs and S100A12 in the diagnosis of inflammatory bowel disease [J]. J Gastroenterol Hepatol, 2013, 28 SUPPL. (3):146.
[19]	Iborra M, Bernuzzi F, Correale C, et al. Identification of serum and tissue micro-RNA expression profiles in different stages of inflammatory bowel disease [J]. Clin Exp Immunol, 2013, 173(2):250-258.
[20]	Wang H, Zhang S, Yu Q, et al. Circulating MicroRNA223 is a New Biomarker for Inflammatory Bowel Disease [J]. Medicine(Baltimore), 2016, 95(5):e2703.
[21]	Link A, Schoenauen K, Le N, et al. Differential expression of micrornas in sera and feces of patients with inflammatory bowel disease [J]. United Eur Gastroenterol J, 2015, 3(5):A236-A237.
[22]	Pott F, Cichon C, Brückner M, et al. MicroRNA-320 as a biomarker to monitor the course of disease activity in experimental colitis as well as in patients with inflammatory bowel disease [J]. United Eur Gastroenterol J, 2(1):A214.
[23]	Ibrahim AF, Weirauch U, Thomas M, et al. MicroRNA replacement therapy for miR-145 and miR-33a is efficacious in a model of colon carcinoma [J]. Cancer Res, 2011, 71(15):5214-5224.
[24]	Lanford RE, Hildebrandt-Eriksen ES, Petri A, et al. Therapeutic silencing of microRNA-122 in primates with chronic hepatitis C virus infection [J]. Science, 2010, 327(5962):198-201.
[25]	Wu F, Zikusoka M, Trindade A, et al. MicroRNAs are differentially expressed in ulcerative colitis and alter expression of macrophage inflammatory peptide-2 alpha [J]. Gastroenterology, 2008, 135(5):1624-1635.
[26]	Simonson B, Das S. MicroRNA Therapeutics: the Next Magic Bullet? [J]. Mini Rev Med Chem, 2015, 15(6):467-474.
[27]	Viscido A, Bagnardi V, Sturniolo GC, et al. Survival and causes of death in Italian patients with ulcerative colitis. A GISC nationwide study [J]. Dig Liver Dis, 2001, 33(8):686-692.
[28]	Feagins L A, Souza R F, Spechler S J. Carcinogenesis in IBD: potential targets for the prevention of colorectal cancer [J]. Nat Rev Gastroenterol Hepatol, 2009, 6(5):297-305.
[29]	Ludwig K, Fassan M, Mescoli C, et al. PDCD4/miR-21 dysregulation in inflammatory bowel disease-associated carcinogenesis [J]. Virchows Arch, 2013, 462(1):57-63.
[30]	Ranjha R, Aggarwal S, Bopanna S, et al. Site-Specific MicroRNA Expression May Lead to Different Subtypes in Ulcerative Colitis [J]. PLoS One, 2015, 10(11):e142869.
[31]	Olaru AV, Selaru FM, Mori Y, et al. Dynamic changes in the expression of MicroRNA-31 during inflammatory bowel disease-associated neoplastic transformation [J]. Inflamm Bowel Dis, 2011, 17(1):221-231.
[32]	Olaru AV, Yamanaka S, Vazquez C, et al. MicroRNA-224 negatively regulates p21 expression during late neoplastic progression in inflammatory bowel disease [J]. Inflamm Bowel Dis, 2013, 19(3):471-480.
[33]	Kunte D, Savkovic S, Qi W, et al. MiR-34a as potential fecal biomarker Colitis-induced Colorectal cancer [J]. Inflammatory Bowel Dis, 2011, 17: S86-S87.

Please choose a citation manager

Content to export